Latest filing published 14 Sept 2026 for Edwards Lifesciences Corp, €18k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andrew M. Dahl (senior executive) discloses dealings in Edwards Lifesciences Corp to SEC (Form 4). Over a trading history stretching from 13 September 2024 to 13 September 2026, the count stands at 10 filings.
Every open-market trade on record is a sale: 2 sales worth €85k. Outside the open market, there are 8 share grants. 2026 to date brings no purchases and 2 sales.
The latest filing, published on 14 September 2026, reports a share grant of €18k in Edwards Lifesciences Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations